Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of ANF-RHO versus Neulasta for prophylaxis of chemotherapy-induced neutropenia in high-risk breast cancer
NL-OMON47295Phase 2Completed
- Sponsor
- Prolong Pharmaceuticals
- Start
- Aug 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ANF-RHO in chemotherapy-induced neutropenia (CIN) (4 arms), sponsored by Prolong Pharmaceuticals. Started Aug 2017; status: completed.
02
Drugs
ANF-RHO
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NL-OMON47295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47295.